What is Cour?
Cour operates at the intersection of biotechnology and advanced therapeutics, focusing on the development of novel medical interventions designed to address significant unmet clinical needs. By leveraging a sophisticated research platform, the company aims to transform patient care through targeted, science-driven solutions. Its market position is bolstered by a robust intellectual property portfolio and strategic alliances with major global pharmaceutical entities, which provide both validation and a pathway for commercialization. The company's focus on high-impact therapeutic areas positions it as a critical player in the evolving landscape of personalized medicine and disease modification.
How much funding has Cour raised?
Cour has raised a total of $185M across 3 funding rounds:
Unspecified
$30M
Series A
$105M
Series B
$50M
Unspecified (2022): $30M with participation from Alpha Wave Ventures
Series A (2024): $105M led by Lumira Ventures and Alpha Wave Global
Series B (2026): $50M supported by JDRF T1D Fund, Pfizer, Alpha Wave Global, Roche, Angelini Ventures, Lumira Ventures, and Sanofi
Key Investors in Cour
Lumira Ventures
Lumira Ventures is Canada's largest life sciences venture capital firm, specializing in investments in healthcare innovators across various stages, from early-stage to revenue-generating biotech, biotherapeutics, and medical devices.
JDRF T1D Fund
The T1D Fund is a scaled venture impact fund dedicated to accelerating treatments, prevention, and cures for the 9 million people living with Type 1 Diabetes through strategic investments in innovative therapies.
Pfizer
Pfizer is a global biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas, including oncology and immunology.
What's next for Cour?
With the successful closure of this Series B round, Cour is poised to enter a critical phase of clinical execution and organizational scaling. The strategic deployment of these funds will likely prioritize the advancement of lead candidates through late-stage clinical trials, alongside the expansion of internal R&D capabilities. Furthermore, the company is expected to leverage its deep-pocketed investor base to explore potential co-development opportunities and strategic partnerships that could expedite the regulatory approval process. As Cour transitions into this next growth stage, the focus will remain on achieving key clinical milestones that demonstrate long-term value for both patients and stakeholders, ultimately aiming to solidify its status as a leader in the biopharmaceutical sector.
See full Cour company page
